导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -12.39% | 3912/4773 |
| 近一周 | -3.20% | 3878/5462 |
| 近一月 | -3.19% | 1601/5421 |
| 近一季 | -1.84% | 1084/5209 |
| 近半年 | -4.96% | 2683/4920 |
| 近一年 | -15.62% | 3705/4366 |
| 近两年 | 27.74% | 2375/2954 |
| 近三年 | 9.24% | 1762/2253 |
| 成立以来 | 24.75% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-14.34% 4642/4961 |
8.89% 2522/5312 |
- - |
- - |
| 2025 | 4.18% 3063/4813 |
-6.37% 3350/3635 |
4.31% 795/4076 |
10.96% 3221/4524 |
-3.86% 3348/4813 |
| 2024 | 25.91% 241/3463 |
-4.61% 1721/2808 |
-8.13% 2170/3014 |
43.04% 28/3129 |
0.45% 1209/3463 |
| 2023 | 4.68% 220/2656 |
4.07% 1057/2280 |
-2.57% 612/2385 |
7.64% 31/2515 |
-4.08% 864/2655 |
| 2022 | -24.31% 1206/2207 |
-17.70% 1246/1919 |
2.08% 1363/2016 |
-15.09% 1213/2113 |
6.12% 390/2208 |
| 2021 | -0.62% 755/1822 |
-13.59% 1158/1255 |
7.83% 664/1330 |
4.83% 316/1466 |
1.73% 817/1822 |
| 2020 | - - |
- - |
- - |
18.00% 92/1164 |
2.16% 1006/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华夏中证全指证券公司ETF联接A VS. 长安沪深300非周期A(740101) |